DRTS Alpha Tau Medical
- 2.405
- +0.005+0.21%
Alpha Tau Medical News
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT,
Buy Rating Affirmed: Anticipating Alpha Tau Medical's Clinical Milestones and Growth Potential in 2024
Express News | HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
Alpha Tau Medical Price Target Cut to $7.00/Share From $8.00 by Piper Sandler
Alpha Tau Medical Price Target Cut to $7.00/Share From $8.00 by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on Alpha Tau Medical, Lowers Price Target to $7
Alpha Tau Medical Ltd (DRTS) Gets a Buy From Piper Sandler
Alpha Tau Medical GAAP EPS of -$0.42
Press Release: Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update - Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT,
Alpha Tau Medical (NASDAQ:DRTS) Is In A Good Position To Deliver On Growth Plans
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Most Popular Amongst Retail Investors Who Own 58%, Insiders Hold 22%
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersReshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 6.7% to $0.26 during Wednesday's after-market session. The company's market cap stands at $4.8 million. Semler Scientific (NASDAQ:SMLR)
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- The overview presentation will review some of the Company's recent achievements, including highly promising interim results from the Company's pancreatic cancer safety and feasibility trial as well
Expert Ratings for Alpha Tau Medical
Alpha Tau Medical (NASDAQ:DRTS) has observed the following analyst ratings within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings31000Last 30D100001M Ago110002
Citigroup Initiates Coverage On Alpha Tau Medical With Buy Rating, Announces Price Target of $8
Citigroup analyst Ashiq Mubarack initiates coverage on Alpha Tau Medical (NASDAQ:DRTS) with a Buy rating and announces Price Target of $8.
Sidoti Events, LLC's Virtual December Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Confere
Press Release: Alpha Tau to Participate in Sidoti Small-Cap Conference
Alpha Tau to Participate in Sidoti Small-Cap Conference JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the
Analysts Are Bullish on These Healthcare Stocks: Alpha Tau Medical Ltd (DRTS), Walgreens Boots Alliance (WBA)
Alpha Tau Announces Interim Results From Safety And Feasibility Trial Of Alpha DaRT Treatment Of Advanced Pancreatic Cancer
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events -- First five patients received cons
Alpha Tau Submits To Japanese PMDA For Pre-Market Approval Of Alpha DaRT In Patients With Recurrent Head And Neck Cancer
Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ:DRTS, DRTSW))))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and HekaBio K.K. ("HekaBio") a Japan-based healthcare investme
Analysis
Price Target
No Data
